Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach

Diabetes Research and Clinical Practice

Volumn 109, Issue 2, 2015, Pages 226-232

  Mbanya, Jean Claude ^a,b   Al Sifri, Saud ^c   Abdel Rahim, Aly ^d   Satman, Ilhan ^e  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b Endocrinology and Metabolic Diseases Unit at the Hospital Central in Yaounde   (Cameroon)

^c AL HADA ARMED FORCES HOSPITAL   (Saudi Arabia)

^d ALEXANDRIA UNIVERSITY   (Egypt)

^e ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Diabetes; Gliclazide; Ramadan

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

CLINICAL EFFECTIVENESS; DATA ANALYSIS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPOGLYCEMIA; INCIDENCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RAMADAN; RELIGION; REVIEW; SYSTEMATIC REVIEW; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; ISLAM; PSYCHOLOGY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FASTING; GLICLAZIDE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; ISLAM;

EID: 84937971131     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.04.030     Document Type: Review

References (37)

1. Guariguata L., Whiting D.R., Hambleton I., Beagley J., Linnenkamp U., Shaw J.E. Global estimates of diabetes prevalence in adults for 2013 and projections for 2035. Diabetes Res Clin Pract 2014, 103(2):137-149.
2. Salti I., Benard E., Detournay B., Bianchi-Biscay M., Le B.C., Voinet C., et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004, 27:2306-2311.
3. Al-Arouj M., Assaad-Khalil S., Buse J., Fahdil I., Fahmy M., Hafez S., et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010, 33:1895-1902.
4. Sotiropoulos A., Skliros E.A., Tountas C., Apostolou U., Peppas T.A., Pappas S.I. Risk factors for severe hypoglycaemia in type 2 diabetic patients admitted to hospital in Piraeus, Greece. East Mediterr Health J 2005, 11:485-489.
5. Zargar A., Basit A., Mahtab H. Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan. J Indian Med Assoc 2005, 103:444-446.
6. Clayton D., Woo V., Yale J.F. Hypoglycemia. Can J Diabetes 2013, 37(Suppl. 1):S69-S71.
7. Note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus 2002, EMA, Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003262.pdf [24.09.14].
8. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005, 28:1245-1249.
9. Al Sifri S., Basiounny A., Echtay A., Al O.M., Harman-Boehm I., Kaddaha G., et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract 2011, 65:1132-1140.
10. Aravind S.R., Ismail S.B., Balamurugan R., Gupta J.B., Wadhwa T., Loh S.M., et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin 2012, 28:1289-1296.
11. Bonds D.E., Miller M.E., Bergenstal R.M., Buse J.B., Byington R.P., Cutler J.A., et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340:b4909.
12. Amiel S.A., Dixon T., Mann R., Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008, 25:245-254.
13. Proks P., Reimann F., Green N., Gribble F., Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002, 51(Suppl. 3):S368-S376.
14. WHO model list of essential medicines 2013, World Health Organization, Available at: http://www.who.int/medicines/publications/essentialmedicines/18th_EML_Final_web_8Jul13.pdf [21.07.14]. 18th ed.
15. Aravind S.R., Al T.K., Ismail S.B., Shehadeh N., Kaddaha G., Liu R., et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin 2011, 27:1237-1242.
16. Bashir M.I., Pathan M.F., Raza S.A., Ahmad J., Khan A.K., Ishtiaq O., et al. Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan. Indian J Endocrinol Metab 2012, 16:503-507.
17. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004, 34:535-542.
18. Schopman J.E., Simon A.C., Hoefnagel S.J., Hoekstra J.B., Scholten R.J., Holleman F. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev 2014, 30:11-22.
19. Hosker J.P., Rudenski A.S., Burnett M.A., Matthews D.R., Turner R.C. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 1989, 38:767-772.
20. Gribble F.M., Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complicat 2003, 17:11-15.
21. Schweizer A., Halimi S., Dejager S. Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan. Vasc Health Risk Manag 2014, 10:15-24.
22. Al-Arouj M., Hassoun A.A., Medlej R., Pathan M.F., Shaltout I., Chawla M.S., et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract 2013, 67:957-963.
23. Rosenstock J., Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007, 14:98-107.
24. Tomkin G.H. Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors. World J Diabetes 2014, 5:636-650.
25. Hassanein M., Abdallah K., Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag 2014, 10:319-326.
26. Landman G.W., de Bock G.H., van Hateren K.J., van Dijk P.R., Groenier K.H., Gans R.O., et al. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. PLOS ONE 2014, 9:e82880.
27. McIntosh B., Cameron C., Singh S.R., Yu C., Ahuja T., Welton N.J., et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2011, 5:e35-e48.
28. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
29. Avogaro A. Treating diabetes today with gliclazide MR: a matter of numbers. Diabetes Obes Metab 2012, 14(Suppl. 1):14-19.
30. Zoungas S., Chalmers J., Neal B., Billot L., Li Q., Hirakawa Y., et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014, 371:1392-1406.
31. Perkovic V., Heerspink H.L., Chalmers J., Woodward M., Jun M., Li Q., et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013, 83:517-523.
32. Monami M., Luzzi C., Lamanna C., Chiasserini V., Addante F., Desideri C.M., et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006, 22:477-482.
33. Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N., Folke F., Hansen M.L., et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011, 32:1900-1908.
34. Rutten G.E.H.M., De Grauw W.J.C., Nijpels G., Houweling S.T., Van de Laar F.A., Bilo H.J., et al. NHG-Standaard Diabetes mellitus type 2 (derde herziening). Huisarts Wet 2013, 56:512-525. [in Dutch].
35. WHO 19th Expert Committee on the Selection and Use of Essential Medicines 2013, World Health Organization, Available at: http://www.who.int/selection_medicines/committees/expert/19/reviews/Glibenclamide_Rev2.pdf?ua=1 [08-12.04.13].
36. Zargar A.H., Siraj M., Jawa A.A., Hasan M., Mahtab H. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast. Int J Clin Pract 2010, 64:1090-1094.
37. Bravis V., Hui E., Salih S., Mehar S., Hassanein M., Devendra D. Ramadan Education and Awareness in Diabetes (READ) programme for Muslims with Type 2 diabetes who fast during Ramadan. Diabet Med 2010, 27:327-331.